<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">Anti-coronavirus protease activity was exhibited by the lopinavir (LPV), and it is proposed as a treatment option for ongoing COVID-19 infection [
 <xref ref-type="bibr" rid="CR174">174</xref>]. Further, a novel vinylsulfone protease inhibitor suggested treating patients suffering from the 2019-nCoV. That would help in the development of broad-spectrum anti-coronaviral agents for future epidemics [
 <xref ref-type="bibr" rid="CR179">179</xref>]. Recently, a breakthrough in search of antivirals came with the elucidation of the SARS-CoV-2 main protease (Mpro) structure. The same could be exploited globally to design some novel drug candidates. Lately, a Deep Docking (DD) platform was used for structure-based virtual screening of nearly 1.3 billion molecules with the potential of 1,000 putative ligands for SARS-CoV-2 Mpro protein [
 <xref ref-type="bibr" rid="CR180">180</xref>].
</p>
